• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Recurrent Strep Throat: How Best to Treat

Article

For patients who have repeated culture-positive episodes of streptococcalpharyngitis, current recommendations include treatment with amoxicillin/clavulanate or clindamycin.

For patients who have repeated culture-positive episodes of streptococcalpharyngitis, current recommendations include treatment with amoxicillin/clavulanate or clindamycin. If the infectious agent is penicillin-sensitiveand especially if the patient responds well to penicillin VK with each episode,would a longer course of penicillin be a more effective treatment?-- MDAll group A streptococci are highly sensitive to penicillin. Therefore,when treatment failure occurs, it is not because of antibioticresistance. Recurrent episodes of "strep throat" are often recurrencesof viral pharyngitis in a patient who is a chronic pharyngealcarrier of streptococci. Penicillins are relatively poor ateradicating carriage, but clindamycin is effective more than 90% of the time.Some authors believe that persistent or recurrent streptococcal infectionsrepresent a situation in which the presence of a co-pathogen capable ofdestroying penicillin or amoxicillin, such as Staphylococcus aureus, enablesthe streptococci to survive. They justify use of a broader-spectrum antibioticon that basis. However, there is no convincing evidence to support this theoryor the use of broader-spectrum agents.-- Stanford T. Shulman, MD
   Professor of Pediatrics
   Feinberg School of Medicine
   Northwestern University
   Chief, Division of Infectious Diseases
   Children's Memorial Hospital
   Chicago

Related Videos
Infectious disease specialist talks about COVID-19 vaccine development
COVID 19 impact on healthcare provider mental health
Physician mental health expert discusses impact of COVID-19 on health care workers
© 2024 MJH Life Sciences

All rights reserved.